Showing results (1731-1740 of 2,088) with videos related to
Sort By:
Pageof 209
The Journal of Cell Biology|March 7, 2018
VASP regulates leukocyte infiltration, polarization, and vascular repair after ischemiaHebatullah Laban, Andreas Weigert, Joana Zink, et al.Redox Biology|July 4, 2021
The hydrogen-peroxide producing NADPH oxidase 4 does not limit neointima development after vascular injury in miceGiulia K Buchmann, Christoph Schürmann, Manuela Spaeth, et al.Cancer Management and Research|April 3, 2023
Sarcoma Patients Admitted to the Intensive Care Unit (ICU): Predictive Relevance of Common Sepsis and Performance ParametersJana K Striefler, Phung T Binder, Franziska Brandes, et al.Plos One|June 3, 2022
Potential role of conventional and speckle-tracking echocardiography in the screening of structural and functional cardiac abnormalities in elderly individuals: Baseline echocardiographic findings from the LOOP studyFlemming Javier Olsen, Søren Zöga Diederichsen, Peter Godsk Jørgensen, et al.Molecular Therapy. Methods & Clinical Development|February 12, 2021
Automated generation of gene-edited CAR T cells at clinical scaleJamal Alzubi, Dominik Lock, Manuel Rhiel, et al.Nature Medicine|October 7, 2008
Molecular mimicry in pauci-immune focal necrotizing glomerulonephritisRenate Kain, Markus Exner, Ricarda Brandes, et al.Journal of Neuro-Oncology|November 5, 2014
Post progression survival in glioblastoma: where are we?Enrico Franceschi, Mario Ermani, Stefania Bartolini, et al.Journal of the American College of Cardiology|October 29, 2025
Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP StudyOliver B Vad, Søren Z Diederichsen, Lucas Y Xing, et al.ESC Heart Failure|July 9, 2025
Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot studyDragana B Kosevic, Una Radak, Petar Vukovic, et al.Neuro-Oncology Practice|March 20, 2025
Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 studyLinda Dirven, Abigirl Machingura, Martin J van den Bent, et al.Pageof 209